A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

NCT02218099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects
Pharmacokinetics of ASP8232
Pharmacodynamics of ASP8232
Chronic Kidney Disease (CKD)
Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG: ASP8232
DRUG: Placebo

Sponsor

Astellas Pharma Europe B.V.